```
XX
AC   AAU07141;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human CRIM1 protein.
XX
KW   CRIM-1; Human; human chromosome 2p21-16.3; ophthalmological;
KW   neuroprotective; renal; osteopathic; dental; vulnerary; immunogen;
KW   antibody; gene therapy; neurodegenerative disease; eye disorder;
KW   cataract; bone morphogenic protein; BMG; renal disease; bone abnormality;
KW   tooth abnormality; wound; S52.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..17
FT                   /label= Signal_peptide
FT   Domain          1..901
FT                   /label= Ectodomain
FT                   /note= "This sequence is specifically claimed in claim
FT                   15"
FT   Protein         18..1036
FT                   /label= Mature_CRIM1
FT   Region          200..207
FT                   /note= "Conserved N-terminal motif"
FT   Region          336..391
FT                   /label= CR_1
FT                   /note= "Cysteine rich repeat"
FT   Region          403..456
FT                   /label= CR_2
FT                   /note= "Cysteine rich repeat"
FT   Misc-difference 414
FT                   /note= "Encoded by GAC"
FT   Region          608..662
FT                   /label= CR_3
FT                   /note= "Cysteine rich repeat"
FT   Region          679..734
FT                   /label= CR_4
FT                   /note= "Cysteine rich repeat"
FT   Region          753..808
FT                   /label= CR_5
FT                   /note= "Cysteine rich repeat"
FT   Region          819..873
FT                   /label= CR_6
FT                   /note= "Cysteine rich repeat"
XX
PN   WO200138519-A1.
XX
PD   31-MAY-2001.
XX
PF   24-NOV-2000; 2000WO-AU01435.
XX
PR   26-NOV-1999;   99AU-0004348.
XX
PA   (UYQU ) UNIV QUEENSLAND.
XX
PI   Little M,  Yamada T,  Holmes G,  Georgas K,  Kolle G,  Wilkinson L;
XX
DR   WPI; 2001-343951/36.
DR   N-PSDB; AAS11601.
XX
PT   Nucleic acids from human chromosome 2p21-16.3 and the encoded peptide,
PT   useful for preventing, diagnosing and treating e.g. eye disease,
PT   especially cataract formation -
XX
PS   Claim 11; Fig 1; 169pp; English.
XX
CC   The invention relates to nucleic acids from human chromosome 2p21-16.3
CC   and the encoded peptide (and mouse and chicken orthologues) that
CC   comprises a PGECCPLP group, an insulin-like growth factor binding protein
CC   (IGFBP)-like domain, cysteine-rich domains, an RGD (undefined) group
CC   and a transmembrane domain. The protein, e.g. CRIM1, interacts with
CC   peptides of the transforming growth factor superfamily. A composition
CC   comprising an expression construct comprising the nucleic acids of the
CC   invention or a mimetic which antagonises or mimics an activity of a CRIM1
CC   polypeptide may be used in a method for modulating the biological
CC   activity of a polypeptide of the bone morphogenic protein (BMP) family.
CC   In this way they may be used to prevent or treat an eye disease,
CC   especially cataract formation. They may also be used to treat
CC   neurodegenerative diseases, renal and kidney disease, bone and tooth
CC   abnormalities, wounds and skin damage, e.g. by use of the nucleic acid in
CC   gene therapy by using antibodies directed against CRIM1 polypeptides.
CC   The present sequence represents human CRIM1 (AKA S52).
XX
SQ   Sequence   1036 AA;

  Query Match             99.1%;  Score 5901;  DB 22;  Length 1036;
  Best Local Similarity   99.2%;  Pred. No. 0;
  Matches 1028;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1 MYLVAGDRGLAGCGHLLVSLLGLLLLPARSGTRALVCLPCDESKCEEPRNRPGSIVQGVC 60
           ||||||||||||||||||||||||| |||||||||||||||||| |||||||||
Db       1 MYLVAGDRGLAGCGHLLVSLLGLLLLLARSGTRALVCLPCDESKCEEPRNCPGSIVQGVC 60

Qy      61 GCCYTCASQGNESCGGTFGIYGTCDRGLRCVIRPPLNGDSLTEYEAGVCEDENWTDDQLL 120
           ||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 GCCYTCASQRNESCGGTFGIYGTCDRGLRCVIRPPLNGDSLTEYEAGVCEDENWTDDQLL 120

Qy     121 GFKPCNENLIAGCNIINGKCECNTIRTCSNPFEFPSQDMCLSALKRIEEEKPDCSKARCE 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 GFKPCNENLIAGCNIINGKCECNTIRTCSNPFEFPSQDMCLSALKRIEEEKPDCSKARCE 180

Qy     181 VQFSPRCPEDSVLIEGYAPPGECCPLPSRCVCNPAGCLRKVCQPGNLNILVSKASGKPGE 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VQFSPRCPEDSVLIEGYAPPGECCPLPSRCVCNPAGCLRKVCQPGNLNILVSKASGKPGE 240

Qy     241 CCDLYECKPVFGVDCRTVECPTVQQTACPPDSYETQVRLTADGCCTLPTRCECLSGLCGF 300
           |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db     241 CCDLYECKPVFGVDCRTVECPPVQQTACPPDSYETQVRLTADGCCTLPTRCECLSGLCGF 300

Qy     301 PVCEVGSTPRIVSRGDGTPGKCCDVFECVNDTKPACVFNNVEYYDGDMFRMDNCRFCRCQ 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 PVCEVGSTPRIVSRGDGTPGKCCDVFECVNDTKPACVFNNVEYYDGDMFRMDNCRFCRCQ 360

Qy     361 GGVAICFTAQCGEINCERYYVPEGECCPVCEDPVYPFNNPAGCYANGLILAHGDRWREDD 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||:||||||
Db     361 GGVAICFTAQCGEINCERYYVPEGECCPVCEDPVYPFNNPAGCYANGLILAHGNRWREDD 420

Qy     421 CTFCQCVNGERHCVATVCGQTCTNPVKVPGECCPVCEEPTIITVDPPACGELSNCTLTRK 480
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||| |
Db     421 CTFCQCVNGERHCVATVCGQTCTNPVKVPGECCPVCEEPTIITVDPPACGELSNCTLTGK 480

Qy     481 DCINGFKRDHNGCRTCQCINTQELCSERKQGCTLNCPFGFLTDAQNCEICECRPRPKKCR 540
           ||||||||||||||||||:|||||||||||||||||||||||||||||||||||||||
Db     481 DCINGFKRDHNGCRTCQCINTEELCSERKQGCTLNCPFGFLTDAQNCEICECRPRPKKCR 540

Qy     541 PIICDKYCPLGLLKNKHGCDICRCKKCPELSCSKICPLGFQQDSHGCLICKCREASASAG 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 PIICDKYCPLGLLKNKHGCDICRCKKCPELSCSKICPLGFQQDSHGCLICKCREASASAG 600

Qy     601 PPILSGTCLTVDGHHHKNEESWHDGCRECYCLNGREMCALITCPVPACGNPTIHPGQCCP 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 PPILSGTCLTVDGHHHKNEESWHDGCRECYCLNGREMCALITCPVPACGNPTIHPGQCCP 660

Qy     661 SCADDFVVQKPELSTPSICHAPGGEYFVEGETWNIDSCTQCTCHSGRVLCETEVCPPLLC 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 SCADDFVVQKPELSTPSICHAPGGEYFVEGETWNIDSCTQCTCHSGRVLCETEVCPPLLC 720

Qy     721 QNPSRTQDSCCPQCTDQPFRPSLSRNNSVPNYCKNDEGDIFLAAESWKPDVCTSCICIDS 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 QNPSRTQDSCCPQCTDQPFRPSLSRNNSVPNYCKNDEGDIFLAAESWKPDVCTSCICIDS 780

Qy     781 VISCFSESCPSVSCERPVLRKGQCCPYCIKDTIPKKVVCHFSGKAYADEERWDLDSCTHC 840
           ||||||||||||||||||||||||:|||||||||||||||||||||||||||||||||||
Db     781 VISCFSESCPSVSCERPVLRKGQCCPYCIEDTIPKKVVCHFSGKAYADEERWDLDSCTHC 840
```

```
                 STVSCPPLPCVEPINVEGSCCPMCPEMYVPEPTNIPIEKTNHRGEVDLEVP 900
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||
                 GGQTLCSTVSCPPLPCVEPINVEGSCCPMCPEMYVPEPTNIPIEKTNHRGEVDLEVP 900

          901 LWPTPSENDIVHLPRDMGHLQVDYRDNRLHPSEDSSLDSIASVVVPIIICLSIIIAFLFI 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
          901 LWPTPSENDIVHLPRDMGHLQVDYRDNRLHPSEDSSLDSIASVVVPIIICLSIIIAFLFI 960

Qy        961 NQKKQWIPLLCWYRTPTKPSSLNNQLVSVDCKKGTRVQVDSSQRMLRIAEPDARFSGFYS 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 NQKKQWIPLLCWYRTPTKPSSLNNQLVSVDCKKGTRVQVDSSQRMLRIAEPDARFSGFYS 1020

Qy       1021 MQKQNHLQADNFYQTV 1036
              ||||||||||||||||
Db       1021 MQKQNHLQADNFYQTV 1036
```

RESULT 6
AAU07142
ID AAU07142 standard; Protein; 1037 AA.
XX
AC [redacted]7142;
XX
DT 24-OCT-2001 (first entry)
XX
DE Mouse CRIM1 protein.
XX
KW CRIM-1; Mouse; human chromosome 2p21-16.3; ophthalmological;
KW neuroprotective; renal; osteopathic; dental; vulnerary; immunogen;
KW antibody; gene therapy; neurodegenerative disease; eye disorder;
KW cataract; bone morphogenic protein; BMG; renal disease; bone abnormality;
KW tooth abnormality; wound; S52.
XX
OS Mus sp.
XX

Key	Location/Qualifiers
Peptide	1..9
	/label= Signal_peptide
Protein	10..1037
	/label= Mature_CRIM1
Region	200..207
	/note= "Conserved N-terminal motif"
Region	336..391
	/label= CR_1
	/note= "Cysteine rich repeat"
Region	403..456
	/label= CR_2
	/note= "Cysteine rich repeat"
Region	608..662
	/label= CR_3
	/note= "Cysteine rich repeat"
Region	679..734
	/label= CR_4
	/note= "Cysteine rich repeat"
Region	753..808
	/label= CR_5
	/note= "Cysteine rich repeat"
Region	819..873
	/label= CR_6
	/note= "Cysteine rich repeat"

XX
RN WO200138519-A1.
XX
RD 31-MAY-2001.
XX
RP 24-NOV-2000; 2000WO-AU01435.
XX
PR 26-NOV-1999; 99AU-0004348.
XX
PA (UYQU) UNIV QUEENSLAND.
XX
AU Little M; Yamada T; Holmes G; Georgas K; Kolle G; Wilkinson L;
XX
DR WPI; 2001-343951/36.
DR N-PSDB; AAS11602.
XX
PT Nucleic acids from human chromosome 2p21-16.3 and the encoded peptide,
PT useful for preventing, diagnosing and treating e.g. eye disease,
PT especially cataract formation -
XX
PS Claim 11; Fig 1; 169pp; English.
XX
CC The invention relates to nucleic acids from human chromosome 2p21-16.3
CC and the encoded peptide (and mouse and chicken orthologues) that
CC comprises a PGECCPLP group, an insulin-like growth factor binding protein
CC (IGFBP)-like domain, cysteine-rich domains, an RGD (undefined) group
CC and a transmembrane domain. The protein, e.g. CRIM1, interacts with
CC peptides of the transforming growth factor superfamily. A composition
CC comprising an expression construct comprising the nucleic acids of the
CC invention or a mimetic which antagonises or mimics an activity of a CRIM1
CC polypeptide may be used in a method for modulating the biological
CC activity of a polypeptide of the bone morphogenic protein (BMP) family.
CC In this way they may be used to prevent or treat an eye disease,
CC especially cataract formation. They may also be used to treat
CC neurodegenerative diseases, renal and kidney disease, bone and tooth
CC abnormalities, wounds and skin damage, e.g. by use of the nucleic acid in
CC gene therapy by using antibodies directed against CRIM1 polypeptides.
CC The present sequence represents mouse CRIM1 (AKA S52).
XX
SQ Sequence 1037 AA;

Query Match 90.8%; Score 5402.5; DB 22; Length 1037;
Best Local Similarity 88.5%; Pred. No. 6.7e-300;
Matches 918; Conservative 51; Mismatches 67; Indels 1; Gaps 1;

```
Qy         1 MYLVAGDRGLAGCGHLLVSLLGLLLLPARSGTRALVCLPCDESKCEEPRNRPGSIVQGVC 60
             |||||| |||||||||| |||||||||                    : |||||||||
Db         1 MYLVAGGRGLAGCGHLSVSLLGLLLLLARSGTRALVCLPCDESKCEEPRSCPGSIVQGVC 60

Qy        61 GCCYTCASQGNESCGGTFGIYGTCDRGLRCVIRPPLNGDSLTEYEAGVCEDENWTDDQLL 120
             |||| || | |||||| :|::| ||||||||||||||||:|||| ||||||:| ||||:
Db        61 GCCYMCARQRNESCGGAYGLHGACDRGLRCVIRPPLNGDSITEYEVGVCEDEDWDDDQLI 120

Qy       121 GFKPCNENLIAGCNIINGKCECNTIRTCSNPFEFPSQDMCLSALKRIEEEKPDCSKARCE 180
             ||:|||||||:|||||||||||| |||||:|||||| :|||||||||||||||||||||||
Db       121 GFEPCNENLISGCNIINGKCECGTIRTCNNPFEFPRKDMCLSALKRIEEEKPDCSKARCE 180

Qy       181 VQFSPRCPEDSVLIEGYAPPGECCPLPSRCVCNPAGCLRKVCQPGNLNILVSKASGKPGE 240
             |:|||||||||:|||||||||||||||||||||:|||||||||||| ||||||||||||||
Db       181 VRFSPRCPEDSILIEGYAPPGECCPLPSRCVCDPAGCLRKVCQPGYLNILVSKASGKPGE 240

Qy       241 CCDLYECKPVFGVDCRTVECPTVQQTACPPDSYETQVRLTADGCCTLPTRCECLSGLCGF 300
             |||||||||||| ||| ||||| ||| || ||||||||||||||||| ||||||||||||
Db       241 CCDLYECKPVFSVDCSTVECPPVQQAVCPLDSYETQVRLTADGCCTLPARCECLSGLCGF 300

Qy       301 PVCEVGSTPRIVSRGDGTPGKCCDVFECVNDTKPACVFNNVEYYDGDMFRMDNCRFCRCQ 360
             ||||||||||||||||||||||||||||:|||||||||:|||||||||||||||||||||
Db       301 PVCEVGSTPRIVSRGDGTPGKCCDVFECVNETKPACVFNSVEYYDGDMFRMDNCRFCRCQ 360

Qy       361 GGVAICFTAQCGEINCERYYVPEGECCPVCEDPVYPFNNPAGCYANGLILAHGDRWREDD 420
             |||:||||||||||:|||||||||||||||||||:|| |||||||||| | ||||||||||
Db       361 GGVSICFTAQCGELNCERYYVPEGECCPVCEDPIYPLNNPAGCYANGQIRAHGDRWREDD 420

Qy       421 CTFCQCVNGERHCVATVCGQTCTNPVKVPGECCPVCEEPTIITVDPPACGELSNCTLTRK 480
             ||||||:||| ||||| |||:| :|||||||||||||||| ||:||||||||||:|  |
Db       421 CTFCQCINGEPHCVATACGQSCMHPVKVPGECCPVCEEPTYITIDPPACGELSNCSLKEK 480

Qy       481 DCINGFKRDHNGCRTCQCINTQELCSERKQGCTLNCPFGFLTDAQNCEICECRPRPKKCR 540
             ||: ||| |||||||||||   :|||   |: |||:|||||||||  |||:|:|||||||||
Db       481 DCVYGFKLDHNGCRTCQCKIREELCLGLKRACTLDCPFGFLTDVHNCELCQCRPRPKKCR 540

Qy       541 PIICDKYCPLGLLKNKHGCDICRCKKCPELSCSKICPLGFQQDSHGCLICKCREASASAG 600
             | :|||:|||| |||||||||||||||||| ||||||||||||||||||||||   |||
Db       541 PTMCDKFCPLGFLKNKHGCDICRCKKCPELPCSKICPLGFQQDSHGCLICKCREVPPSAG 600
```